187 related articles for article (PubMed ID: 19139883)
1. A possible mechanism of intravesical BCG therapy for human bladder carcinoma: involvement of innate effector cells for the inhibition of tumor growth.
Higuchi T; Shimizu M; Owaki A; Takahashi M; Shinya E; Nishimura T; Takahashi H
Cancer Immunol Immunother; 2009 Aug; 58(8):1245-55. PubMed ID: 19139883
[TBL] [Abstract][Full Text] [Related]
2. Effect of different Bacillus Calmette-Guerin substrains on growth inhibition of T24 bladder cancer cells and cytokines secretion by BCG activated peripheral blood mononuclear cells of PBMCs.
Janaszek-Seydlitz W; Prygiel M; Bucholc B; Wiatrzyk A; Czajka U; Górska P; Soliwoda U
Adv Clin Exp Med; 2014; 23(6):877-84. PubMed ID: 25618112
[TBL] [Abstract][Full Text] [Related]
3. Bacillus Calmette-Guérin-pulsed dendritic cells stimulate natural killer T cells and gammadeltaT cells.
Naoe M; Ogawa Y; Takeshita K; Morita J; Iwamoto S; Miyazaki A; Yoshida H
Int J Urol; 2007 Jun; 14(6):532-8; discussion 538. PubMed ID: 17593099
[TBL] [Abstract][Full Text] [Related]
4. The liposome-incorporating cell wall skeleton of Mycobacterium bovis bacillus Calmette-Guéin can directly enhance the susceptibility of cancer cells to lymphokine-activated killer cells through up-regulation of natural-killer group 2, member D ligands.
Miyazaki J; Kawai K; Kojima T; Oikawa T; Joraku A; Shimazui T; Nakaya A; Yano I; Nakamura T; Harashima H; Akaza H
BJU Int; 2011 Nov; 108(9):1520-6. PubMed ID: 21314815
[TBL] [Abstract][Full Text] [Related]
5. Enhanced antigen-presenting activity and tumour necrosis factor-alpha-independent activation of dendritic cells following treatment with Mycobacterium bovis bacillus Calmette-Guérin.
Kim KD; Lee HG; Kim JK; Park SN; Choe IS; Choe YK; Kim SJ; Lee E; Lim JS
Immunology; 1999 Aug; 97(4):626-33. PubMed ID: 10457216
[TBL] [Abstract][Full Text] [Related]
6. Poly(I:C) potentiates Bacillus Calmette-Guérin immunotherapy for bladder cancer.
Ayari C; Besançon M; Bergeron A; LaRue H; Bussières V; Fradet Y
Cancer Immunol Immunother; 2016 Feb; 65(2):223-34. PubMed ID: 26759009
[TBL] [Abstract][Full Text] [Related]
7. Perforin-mediated lysis of tumor cells by Mycobacterium bovis Bacillus Calmette-Guérin-activated killer cells.
Brandau S; Suttmann H; Riemensberger J; Seitzer U; Arnold J; Durek C; Jocham D; Flad HD; Böhle A
Clin Cancer Res; 2000 Sep; 6(9):3729-38. PubMed ID: 10999767
[TBL] [Abstract][Full Text] [Related]
8. Cytokine production by the human bladder carcinoma cell line T24 in the presence of bacillus Calmette-Guerin (BCG).
de Reijke TM; Vos PC; de Boer EC; Bevers RF; de Muinck Keizer WH; Kurth KH; Schamhart DH
Urol Res; 1993; 21(5):349-52. PubMed ID: 8279092
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-10 inhibits Mycobacterium bovis bacillus Calmette-Guérin (BCG)-induced macrophage cytotoxicity against bladder cancer cells.
Luo Y; Han R; Evanoff DP; Chen X
Clin Exp Immunol; 2010 Jun; 160(3):359-68. PubMed ID: 20148913
[TBL] [Abstract][Full Text] [Related]
10. Complement C5a anaphylatoxin is an innate determinant of dendritic cell-induced Th1 immunity to Mycobacterium bovis BCG infection in mice.
Moulton RA; Mashruwala MA; Smith AK; Lindsey DR; Wetsel RA; Haviland DL; Hunter RL; Jagannath C
J Leukoc Biol; 2007 Oct; 82(4):956-67. PubMed ID: 17675563
[TBL] [Abstract][Full Text] [Related]
11. Immunomodulatory effects of recombinant BCG expressing pertussis toxin on TNF-alpha and IL-10 in a bladder cancer model.
Chade DC; Borra RC; Nascimento IP; Villanova FE; Leite LC; Andrade E; Srougi M; Ramos KL; Andrade PM
J Exp Clin Cancer Res; 2008 Nov; 27(1):78. PubMed ID: 19040745
[TBL] [Abstract][Full Text] [Related]
12. Natural Killer Anti-Tumor Activity Can Be Achieved by
Esteso G; Aguiló N; Julián E; Ashiru O; Ho MM; Martín C; Valés-Gómez M
Front Immunol; 2021; 12():622995. PubMed ID: 33708215
[TBL] [Abstract][Full Text] [Related]
13. Recombinant Mycobacterium bovis bacillus Calmette-Guérin (BCG) expressing mouse IL-18 augments Th1 immunity and macrophage cytotoxicity.
Luo Y; Yamada H; Chen X; Ryan AA; Evanoff DP; Triccas JA; O'Donnell MA
Clin Exp Immunol; 2004 Jul; 137(1):24-34. PubMed ID: 15196240
[TBL] [Abstract][Full Text] [Related]
14. Murine bladder carcinoma cells present antigen to BCG-specific CD4+ T-cells.
Lattime EC; Gomella LG; McCue PA
Cancer Res; 1992 Aug; 52(15):4286-90. PubMed ID: 1638541
[TBL] [Abstract][Full Text] [Related]
15. What are the immunologically active components of bacille Calmette-Guérin in therapy of superficial bladder cancer?
Zlotta AR; Van Vooren JP; Denis O; Drowart A; Daffé M; Lefèvre P; Schandene L; De Cock M; De Bruyn J; Vandenbussche P; Jurion F; Palfliet K; Simon J; Schulman CC; Content J; Huygen K
Int J Cancer; 2000 Sep; 87(6):844-52. PubMed ID: 10956396
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of bacillus Calmette-Guerin mediated natural killer cell activation.
Suttmann H; Jacobsen M; Reiss K; Jocham D; Böhle A; Brandau S
J Urol; 2004 Oct; 172(4 Pt 1):1490-5. PubMed ID: 15371877
[TBL] [Abstract][Full Text] [Related]
17. The immunotherapeutic effects of recombinant Bacillus Calmette-Guérin resistant to antimicrobial peptides on bladder cancer cells.
Cho MJ; Kim MJ; Kim K; Choi YW; Lee SJ; Whang YM; Chang IH
Biochem Biophys Res Commun; 2019 Jan; 509(1):167-174. PubMed ID: 30579607
[TBL] [Abstract][Full Text] [Related]
18. Dissecting the immunobiological effects of Bacillus Calmette-Guérin (BCG) in vitro: evidence of a distinct BCG-activated killer (BAK) cell phenomenon.
Böhle A; Thanhäuser A; Ulmer AJ; Ernst M; Flad HD; Jocham D
J Urol; 1993 Dec; 150(6):1932-7. PubMed ID: 8230540
[TBL] [Abstract][Full Text] [Related]
19. Importance of urinary interleukin-18 in intravesical immunotherapy with bacillus calmette-guérin for superficial bladder tumors.
Eto M; Koga H; Noma H; Yamaguchi A; Yoshikai Y; Naito S
Urol Int; 2005; 75(2):114-8. PubMed ID: 16123563
[TBL] [Abstract][Full Text] [Related]
20. Cytokine-mediated antitumor effect of bacillus Calmette-Guérin on tumor cells in vitro.
Kurisu H; Matsuyama H; Ohmoto Y; Shimabukuro T; Naito K
Cancer Immunol Immunother; 1994 Oct; 39(4):249-53. PubMed ID: 7954527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
